127 related articles for article (PubMed ID: 15254059)
1. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
[TBL] [Abstract][Full Text] [Related]
2. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.
Takigawa N; Segawa Y; Kishino D; Fujiwara K; Tokuda Y; Seki N; Shinkai T; Watanabe Y; Hiraki S; Kozuki T; Gemba K; Tabata M; Kiura K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2004 Sep; 54(3):230-6. PubMed ID: 15127232
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
[TBL] [Abstract][Full Text] [Related]
6. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
[TBL] [Abstract][Full Text] [Related]
7. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
8. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer.
Tsunoda T; Koizumi T; Hayasaka M; Hirai K; Koyama S; Takabayashi Y; Fujimoto K; Kubo K
Cancer Chemother Pharmacol; 2004 Aug; 54(2):173-7. PubMed ID: 15127230
[TBL] [Abstract][Full Text] [Related]
11. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
13. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
[TBL] [Abstract][Full Text] [Related]
15. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer.
Cho SH; Go SI; Lee GW; Kang JH; Kim HG; Kim SH; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS
Lung Cancer; 2010 Jul; 69(1):94-8. PubMed ID: 19796840
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
ten Tije AJ; Verweij J; Carducci MA; Graveland W; Rogers T; Pronk T; Verbruggen MP; Dawkins F; Baker SD
J Clin Oncol; 2005 Feb; 23(6):1070-7. PubMed ID: 15718305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
